Avidity Biosciences specializes in developing therapies based on oligonucleotides for the treatment of various serious diseases, including rare muscle diseases such as myotonic dystrophy type 1, Duchenne Muscular Dystrophy, and facioscapulohumeral muscular dystrophy. Their lead product candidate AOC 1001 is currently in development for the treatment of myotonic dystrophy type 1. Additionally, the company offers Lumizyme therapy for Pompe diseases.